1. A method for treating fibrosis in a subject, which comprises administering to the subject an antibody specifically binding to LOXL2 at a dose of 1, 3, 5, 15 or 30 mg / kg, which alleviates the symptoms of fibrosis. The method of claim 1, wherein the fibrosis is liver fibrosis or pulmonary fibrosis. The method according to claim 2, which causes a decrease in cross-linking of collagen, expression of smooth muscle α-actin by stromal cells or the number of leukocytes in the lungs of a subject. A method for treating arthritis in a subject, which comprises administering to the subject an antibody specifically binding to LOXL2 at a dose of 1, 3, 5, 15, or 30 mg / kg, which alleviates the symptoms of arthritis. 5. A method of treating a tumor in a subject, which comprises administering to the subject an antibody specifically binding to LOXL2 at a dose of 1, 3, 5, 15 or 30 mg / kg, which alleviates the symptoms of the tumor, wherein the tumor is selected from the group consisting of breast, pancreas tumors and ovaries. 6. The method according to claim 5, which causes a decrease in the average tumor volume or desmoplasia in a subject. The method of claim 5, further comprising administering to the subject an antineoplastic or chemotherapeutic agent. The method according to claim 7, wherein the agent is selected from the group consisting of taxotere, taxol, sorafenib, gemzar and 5-fluorouracil. The method of claim 1, wherein the antibody is administered twice a week. The method of claim 1, wherein the antibody is administered at a dose of about 1 mg / kg. The method of claim 1, wherein the antibody is administered at a dose of about 3 mg / kg. The method of claim 1, wherein the antibody is administered at a dose of about 5 mg / kg. The method of claim 1, wherein the antibody is administered at a dose of about 15 mg / kg. The method of claim 1, wherein the antibody is administered at a dose of about 30 mg / kg.1. Способ лечения фиброза у субъекта, который включает введение су
